Ltr Pharma
LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.
Short position
Ltr Pharma (ASX:LTP) has 0.08% of its shares on issue reported as short positions as of 5 Oct 2026, or about 147,793 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.53% in July 2024. LTP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Ltr Pharma (LTP) company profile
Profile, insiders and operations
Company
AI-generated research profile of Ltr Pharma
LTP intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links